Among the re-treated patients, almost 90% achieved symptom control (UAS7 ≤6) within 3 months. During both dosing periods, Xolair 150mg and 300mg were well-tolerated
Most products were accurate to their stated label, however most products did contain at least 1 unspecified antigen, for instance, "brand of nut-free cookies contained gluten, whereas a gluten-free brand contained a peanut allergen," the authors write.
The authors reported that zero patients developed an immediate hypersensitivity reaction during these courses of administration.
Results found that 4 children initially treated with PPOIT and 6 treated with placebo had allergic reactions to peanut intake, none experience prophylaxis.
After adjusting for socioeconomic index, diabetes, level of education, sex and age, an increased risk of pneumococcal infection among celiac disease patients was noted.
In March and May 2017, two patients given intravenous (IV) infusions of curcumin emulsion compounded with polyethylene glycol (PEG) 40 castor oil reported having immediate hypersensitivity reactions.
The company has indicated that if the new auto-injector is approved they expect it to be available for patients in the first half of 2018.
Symjepi should only be injected into the anterolateral aspect of the thigh; injection into other areas such as the buttocks or the hands and feet may result in adverse effects and may also not provide effective treatment of anaphylaxis.
While testing did not reveal the presence of the microorganism, the recall is being conducted out of an abundance of caution, as use of contaminated product can be especially concerning for immunocompromised patients.
Zerviate is the first topical ocular formulation of cetirizine.
States in the Midwest and South appear to have the highest prevalence of both alpha-gal allergy and rickettsial diseases transmitted by the Lone Star tick or Amblyomma americanum.
In aclinical trial, AllerVarx decreased total symptom scores by ~70% and decreased the use of anti-allergic meds by ~73%.
Patients at a community clinic in San Diego were asked to bring in unused, expired EpiPens so they could be examined.
The data revealed the most common indications for short-term corticosteroid use to be upper respiratory tract infections, spinal conditions, and allergies.
The recall affects both the EpiPen Auto-Injector 0.15mg and 0.3mg strengths and the product was distributed by Mylan Specialty between December 2015 and July 2016.
Xyzal Allergy 24HR is recommended for use in patients aged ≥6 years, with Children's Xyzal Allergy 24HR oral solution is recommended for use in patients aged ≥2 years.
Results showed that GSP 301 was tied to statistically significant improvements from baseline for the primary endpoint when compared to placebo (P<0.001), olopatadine (P=0.028), and mometasone (P=0.019).
SPT and sIgE displayed moderate agreement in their correlation with allergic disease in a cohort of 10-year olds, and showed no significant difference for the area under the curve for allergic diseases.
A triple combination probiotic was found to improve the rhinoconjunctivitis-specific quality of life for individuals with seasonal allergies when compared with placebo.
Odactra provides patients an alternative treatment to allergy shots.
A mice model demonstrated that treating severe influenza with Singulair or Accolate may prevent severe pneumonia.
Propel Contour features an hourglass design and is specifically designed to conform to the sinus ostia.
This clinical report from the American Academy of Pediatrics is an update on their 2007 clinical report.
GSK Consumer Healthcare announced the availability of Flonase Sensimist Allergy Relief (fluticasone furoate), an over-the-counter (OTC) treatment for symptoms associated with seasonal and perennial allergies for patients aged ≥12 years.
Transverse myelitis (TM) can be a manifestation of celiac disease (CD) in young children, according to a case report published online February 2 in Pediatrics.
Reactions can occur within minutes of exposure.
Both tablets and oral solution will be available over-the-counter.
Data from a retrospective cohort study found that about 1 in 5 non-steroidal anti-inflammatory drug (NSAID) adverse drug reactions is a hypersensitivity reaction.
Kaléo announced that Auvi-Q (epinephrine injection) Auto-injector will be available in pharmacies beginning February 14th.
In a position paper published in the January issue of the Journal of Pediatric Gastroenterology and Nutrition, guidance is presented in relation to complementary foods and their introduction into an infant's diet.
"We expect that widespread implementation of these guidelines will prevent the development of peanut allergy in many susceptible children and ultimately reduce the prevalence of peanut allergy in the United States," said NIAID Director Anthony S. Fauci, MD.
Astellas and Immunomic announced that the Food and Drug Administration (FDA) has granted Fast Track designation to its candidate ASP0892 for the mitigation of severe hypersensitivity reactions due to peanut allergy.
Mylan announced the launch of Epinephrine Injection Auto-Injector, the authorized generic for EpiPen Auto-Injector.
Findings from a study published in the Annals of Allergy, Asthma & Immunology suggest the ongoing difficulty in diagnosing anaphylaxis as evident by the low prescribing rates of epinephrine auto-injector in cases of anaphylaxis.
Initial trial results have shown that a wearable patch, which delivers small amounts of peanut protein, can protect children and young adults with peanut allergies from the effects of accidental ingestion or exposure.
Kaléo announced today that they will reintroduce AUVI-Q (epinephrine injection, USP) to the U.S. market in the first half of 2017.
About 80% of patients with a penicillin allergy lose their sensitivity by 10 years following their reaction.
Taking antibiotics at a very young age could increase the risk of certain allergic conditions later in life, according to research presented at the annual European Respiratory Society International Congress, held from in London.
Mylan announced it is taking steps to expand patient access to EpiPen (epinephrine injection) and EpiPen Jr. Auto-Injectors by enhancing existing programs to assist patients who face higher costs.
A retrospective study found that the nausea and vomiting preventative treatment, ondansetron, was more effective than traditional therapy in inducing remission of vomiting in patients with acute food protein induced enterocolitis syndrome (FPIES).
A study reported that close to 80% of peanut-allergic preschool children successfully integrated peanut-containing foods into their diets after treatment with peanut oral immunotherapy (OIT).
For patients with allergic rhinitis (AR), house dust mite (HDM) sublingual immunotherapy is effective and seems safe, according to a study published online July 29 in Allergy.
The OTC treatment is for symptoms associated with seasonal and perennial allergies in patients aged ≥2 years.
Adamis Pharmaceuticals announced that the Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to the New Drug Application (NDA) for Epinephrine Injection USP 1:1000 0.3mg Pre-filled Single Dose Syringe (PFS) for the emergency treatment of acute anaphylaxis.
For the management of angiotensin-converting enzyme inhibitor (ACEI)-induced angioedema, use of fresh frozen plasma and complement 1 esterase (C1) inhibitor appear to be safe and effective whereas ecallantide should be avoided, a study published in the American Journal of Health-System Pharmacy concluded.
The labeling for several epinephrine injection products has been updated to include information regarding injection-related injury and serious infections at the injection site.
Xlear have announced that their line of xylitol-based products for adults with upper respiratory problems will be available at 1,300 Target stores nationwide.
Older patients taking anticholinergic (AC) medication scored significantly lower on three separate brain atrophy and dysfunction tests compared to matched controls who took no AC medication.
The Food and Drug Administration (FDA) issued a safety communication recommending against the use of OxySure Portable Emergency Oxygen System, Model 615.
NOW Health Group announced a voluntary recall of 6 dietary supplements that were mislabeled due to a printing error by the label supplier.
The FDA has proposed a ban on most powdered gloves in the United States.
Early changes in immune T-cell populations may aid researchers in determining which patients with peanut allergies will respond well to oral immunotherapy. They can also pinpoint which immune mechanisms are involved in the response, according to a study conducted by Stanford University researchers.
Less than 40% of parents recall their pediatricians explaining when they are to use epinephrine in the event of their child having an allergic reaction.
Delaying immunization with diphtheria-tetanus-acellular pertussis (DTaP) vaccine was not associated with reduced risk of food allergy but children with delayed DTaP were found to have less eczema and used less eczema drugs, according to a study published in Allergy.
Children with certain allergies are at double the risk of developing high blood pressure and cholesterol, a study conducted by researchers at Northwestern Medicine reported.
Sanofi announced the voluntary recall of all Auvi-Q (epinephrine injection) due to a potentially inaccurate dosage delivery.
Merck has issued a letter to healthcare professionals letting them know that Nasonex (mometasone furoate monohydrate) Nasal Spray 50mcg is currently out of stock due to a manufacturing issue.
Infants who developed intolerance to cow's milk showed significant differences in gut bacteria after being treated with probiotics, a new study conducted by researchers from the University of Chicago has found.
The American Academy of Pediatrics (AAP) has issued interim guidance, in conjunction with 10 other medical organizations, supporting early rather than delayed peanut introduction during the period of complementary food introduction in infants.
In a new article published in the Annals of of Allergy, Asthma and Immunology, experts recommend the use of epinephrine for all severe allergic reactions, even for patients at risk of an anaphylactic reaction.
National Pharma announced the launch of Naramin (diphenhydramine), an oral solution in prefilled single-dose whistles.
DBV Technologies announced that based its meeting with the Food and Drug Administration (FDA), it plans to initiate a global Phase 3 study of its investigational Viaskin Peanut epicutaneous immunotherapy (EPIT) patch for the treatment of peanut allergies.
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to AR101, an oral immunotherapy for children and adolescents 4 to 17 years of age who are allergic to peanuts.
Aimmune Therapeutics announced that the Phase 2 study of a novel investigational oral immunotherapy (AR101) for the treatment of peanut allergy met its primary endpoint of tolerating a cumulative amount of peanut protein of at least 443mg.
The American College of Allergy, Asthma, and Immunology has developed an infographic titled "Scope and Impact of the Asthma Epidemic" that addresses vital statistics for asthma sufferers as well as the benefits of consulting an allergist for their care.
An over-the-counter (OTC) medication indicated to treat allergy symptoms could potentially be used to treat hepatitis C virus (HCV) infection after a new study showed that it limited HCV virus activity in infected mice. The research was funded by the National Institutes of Health (NIH).
A new blood test may be able to predict who will have severe allergic reactions to foods, researchers from Mount Sinai have reported.
The Food and Drug Administration (FDA) has strengthened an existing warning regarding serious and potentially fatal allergic reactions that can occur with Feraheme (ferumoxytol; AMAG Pharmaceuticals).
Despite the widely accepted assumption that the rise in allergic disorders may be due to improved hygiene, a new study has found no connection between development of allergies and asthma and personal hygiene or home cleanliness.
A new study has found that maternally reported gastrointestinal (GI) symptoms in children are more common in children with autism spectrum disorder (ASD) in the first three years of life compared to children with typical development or developmental delay (DD).
The Food and Drug Administration (FDA) is recommending that manufacturers stop using the labels "latex-free" or "does not contain latex" due to the scientific inaccuracy of these claims.
Allergic disease associated with Cannabis sativa and use has been reported with increasing frequency, although it is still relatively uncommon. A new article published in the Annals of Allergy, Asthma and Immunology presents data on how Cannabis sativa can act as an allergen.
Introducing peanut products into the diets of infants at high risk of developing peanut allergy was safe and led to an 81% reduction in the subsequent allergy development, reports a new study.
Meda announced that the Food and Drug Administration (FDA) has approved Dymista (azelastine HCl and fluticasone propionate) for the relief of symptoms of seasonal allergic rhinitis (SAR) in patients ages 6-11 who require treatment with both components.
Data from a Phase 2b trial showed that patients with peanut allergy using Viaskin Peanut (DBV Technologies) showed significant improvement using this epicutaneous immunotherapy (EPIT) after one year.
Loratadine, an antihistamine found in over-the-counter allergy medicines, may be able to help kill the bacteria associated with Lyme disease (Borrelia burgdorferi).
A new oral therapy that combines a probiotic and peanut protein appears to be a successful immunotherapy for peanut allergy, based on a study conducted by researchers at Murdoch Childrens Research Institute at the Royal Children's Hospital in Australia.
The Food and Drug Administration (FDA) is warning about a slightly increased risk of cardiovascular and cerebrovascular events among patients being treated with Xolair (omalizumab; Genentech and Novartis) for asthma compared to those not treated with Xolair.
Vicks announced the launch of QlearQuil, a line of over-the-counter (OTC) products for the treatment of sinus and allergy symptoms.
The Food and Drug Administration (FDA) has issued an alert regarding an ingredient commonly found in gluten-free products that may cause anaphylaxis in patients with a legume allergy.
GlaxoSmithKline announced that the FDA has approved Flonase Allergy Relief (fluticasone propionate 50mcg spray) as a once-daily over-the-counter (OTC) treatment indicated for symptoms of seasonal and perennial allergic and nonallergic rhinitis in patients ≥4 years of age
Greer laboratories announced the launch of Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract) sublingual allergy immunotherapy tablet.
Ranbaxy has announced a voluntary recall of 29,790 blister packs of an over-the-counter (OTC) allergy medication in the U.S. after an unacceptable number of blister defects were identified.
The FDA announced the approval of Ragwitek (Ambrosia artemisiifolia; Merck), the first sublingual allergen extract to treat short ragweed pollen induced allergic rhinitis, with or without conjunctivitis.
Merck announced that the FDA has approved Grastek (Timothy grass pollen allergen extract) Tablet for Sublingual Use as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis.
Greer Laboratories announced that the FDA has approved Oralair sublingual allergy immunotherapy tablet for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis.
Genentech announced that the FDA has approved Xolair (omalizumab) injection for the treatment of chronic idiopathic urticaria (CIU).
Allergy prevalence is uniform across varying regions in the U.S, except in children ≤5 years old, according to an NIH study.
Adjuvant high-dose vitamin D3 is beneficial for patients with chronic urticaria.
"Talking" medical devices and apps, among other techy health-focused inventions, can help people manage everyday wellness routines, such as taking pills and checking blood sugar levels, as well as dire medical circumstances.
Sanofi and its consumer healthcare division Chattem announced that Nasacort (triamcinolone acetonide) Allergy 24hr Nasal Spray is now available over-the-counter (OTC).
Peanut oral immunotherapy (OIT) is efficacious for desensitization of children with peanut allergy.
Early allergen exposure may increase tolerance and lowers risk of childhood food allergy.
The delay of solid foods until ≥17 weeks of age and continued breastfeeding when cow's milk protein is introduced to infants' diets correlate with a reduced likelihood of food allergies.
President Obama signed a new law meant to increase the availability of life-saving epinephrine in U.S. schools on Wednesday.
Merck announced data for its investigational Timothy grass sublingual allergy immunotherapy tablet (MK-7243) to treat the underlying cause of allergic rhinitis.
Non-celiac wheat sensitivity (NCWS) may be a non-immunoglobulin E-mediated food allergy.
Mothers' receipt of immunotherapy during pregnancy may reduce the risk of any type of allergy in offspring.
Multiple chronic conditions are associated with worse health in terms of activities of daily living and health-related quality of life in older adults.